deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT02201992

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions ALK Gene Rearrangement ALK Gene Translocation ALK Positive Stage IB Non-Small Cell Lung Carcinoma AJCC v7 Stage II Non-Small Cell Lung Cancer AJCC v7 Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions Clinical Observation Crizotinib Laboratory Biomarker Analysis
Updated 19 times since 2017 Last updated: Dec 17, 2025 Started: Mar 23, 2015 Primary completion: May 1, 2036 Completion: May 1, 2036
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on ALK Gene Rearrangement and ALK Gene Translocation, this trial is ongoing. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 19 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Jun 2020 · 12 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Jul 2023 · 6 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 8 months · monthly snapshot

Change History

19 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Sep 2025 — Jan 2026 [monthly]

    Recruiting PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE3

  4. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  5. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE3

▶ Show 14 earlier versions

  1. Jul 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

  2. Jan 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  3. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  4. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

    Status: Unknown Status → Recruiting

  5. Jun 2022 — Jul 2022 [monthly]

    Unknown Status PHASE3

    Status: Recruiting → Unknown Status

  6. Jan 2021 — Jun 2022 [monthly]

    Recruiting PHASE3

  7. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Jun 2019 — Jun 2020 [monthly]

    Recruiting PHASE3

  9. Mar 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  10. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE3

  11. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  12. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  13. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ECOG-ACRIN Cancer Research Group
  • National Cancer Institute (NCI)
Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Abilene, United States , Adrian, United States , Aitkin, United States , Akron, United States , Albany, United States , Albuquerque, United States , Alexandria, United States , Allentown, United States , Alliance, United States and 889 more locations